Initial therapy of chronic lymphocytic leukemia

Area of Science:

• Oncology
• Hematology
• Immunology

Background:

• Chronic lymphocytic leukemia (CLL) is a heterogeneous lymphoid malignancy.
• Treatment decisions for CLL are guided by disease stage, symptoms, and patient-specific factors.

Purpose of the Study:

• To outline current therapeutic strategies for chronic lymphocytic leukemia (CLL).
• To discuss treatment selection based on prognostic factors and patient fitness.

Main Methods:

• Review of established treatment guidelines for chronic lymphocytic leukemia (CLL).
• Analysis of therapeutic options including chemoimmunotherapy, targeted agents, and supportive care.

Main Results:

• Chemoimmunotherapy (fludarabine, cyclophosphamide, rituximab) is standard for fit CLL patients.
• Unfit patients may benefit from anti-CD20 antibodies (obinutuzumab, rituximab, ofatumumab) with chlorambucil.
• Patients with del(17p) or TP53 mutations are candidates for ibrutinib or idelalisib plus rituximab.

Conclusions:

• Treatment choice for CLL hinges on disease characteristics and patient comorbidities.
• Ongoing clinical trials are exploring novel kinase inhibitors and immunotherapeutics for improved CLL outcomes.